AASLD
8-12 November, 2019
Boston, Massachusetts
ENYO Pharma attended the AASLD meeting in Boston and presented four posters as well as performed an oral presentation around FXR agonists in HBV and NASH.
Download the poster (PDF) Download the poster (PDF) Download the poster (PDF) Download the poster (PDF)During the conference, ENYO Pharma sponsored a Symposium to discuss recent advances in the understanding of the replication of Hepatitis B (HBV) and the potential ability of Farnesoid X receptor (FXR) agonists, such as EYP001, to provide a functional cure for HBV. The session “FXR agonist targeting HBV: a new therapeutic class?” was led by the following Key Opinion Leaders (KOLs):
– Prof. Fabien Zoulim (Inserm Lyon): General overview of HBV replication, the role of HBx and cccDNA as targets in the landscape of new HBV treatments
– Prof. Stephan Urban (Heidelberg University): Update on HBV transcription regulation-ready as a target for therapeutic intervention
– Prof. Robert Gish (HepB Foundation): Presentation of the EYP001 FXR agonist phase 1b data as an example of a new therapeutic option in development
Read next in 'Events'
- The 2024 international workshop on Alport syndrome
- ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
- 6th CKD Summit – Chronic Kidney Disease Drug Development
- ASN Kidney Week
- Alport Connect 2023, the annual Alport syndrome patient and family meeting in US